92470

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Mail Box and Bldg/Room Location		esults Format Preferre	II: 1919193 (/)	4/28/03 49 ER DISK E-MAIL
If more than one search is subr	4モル nitted, please prior	itize searches in ord	er of need.	
Please provide a detailed statement of the Include the elected species or structures, utility of the invention. Define any term known. Please attach a copy of the cover	***************** e search topic, and descrikeywords, synonyms, active that may have a special	be as specifically as possib cronyms, and registry numb meaning. Give examples	t*************************************	with the concent or
Title of Invention:		. •••	•	
Inventors (please provide full names):			1	
Earliest Priority Filing Date:				100
*For Sequence Searches Only * Please incluse appropriate serial number. HC Nordinal Landburgh L	2 - 1 H	N Cm Cm N, M=	N-H/ Tec	C Mary Jane Ruhl th. Info. Specialist, STIC TC-1600 CM-1, Room 6A-06 Phone: 605-1155
Note - 1-110 10	Mr Case per	120+17-6	acres) .
			:	
STAFF USE ONLY	Type of Search	**************************************	cost where appli	******
Searcher:	NA Sequence (#)			
Searcher Phone #:	AA Sequence (#)	_ Dialog		
Searcher Location:	Structure (#)		•	
Date Searcher Picked Up: 4/28/03	Bibliographic		14	
Date Completed: 5/1/03	Litigation	Lexis/Nexis		A
Searcher Prep & Review Time:	Fulltext	Sequence Systems		
Clerical Prep Time:				•
Online Time:	Patent Family	WWW/Internet	<u>.</u> .	
PTO 1500 (8 01)	Other .	Other (specify)	•	

=> d his

L6

(FILE 'HOME' ENTERED AT 10:50:24 ON 01 MAY 2003)

FILE 'REGISTRY' ENTERED AT 10:50:33 ON 01 MAY 2003 L1STR L***

L2 17 S L1 L3 STR L1 L4L5

1 5 L3 NOT L4
10 S L3 NOT L4 FULL 10 complex, only 2 appear in lit.

- see of one stat for structures

FILE 'HCAPLUS' ENTERED AT 12:43:33 ON 01 MAY 2003
2 S L6 2 City from CA Plus

L7

FILE 'CAOLD' ENTERED AT 12:46:33 ON 01 MAY 2003 0 S L7 Docks from CADLA rs


* List of 10 compds attacked

=> d que stat 17 L3 STR 0 18 C 19 10 - N-G2-- N 13 G1 16

VAR G1=C/H REP G2 = (1-3) C NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE STR



VAR G1=C/H REP G2=(1-3) C NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED ECOUNT IS M1-X5 C AT 19

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L6 10 SEA FILE=REGISTRY SSS FUL L3 NOT L4

L7 2 SEA FILE=HCAPLUS ABB=ON L6

=> d ibib abs hitstr 17 1-2

ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS ACCESSION NUMBER: 2002:676018 HCAPLUS

DOCUMENT NUMBER: 137:216824

TITLE: Preparation of xanthine derivatives as

dipeptidylpeptidase-IV inhibitors

Himmelsbach, Frank; Mark, Michael; Eckhardt, Matthias; INVENTOR(S):

Langkopf, Elke; Maier, Roland; Lotz, Ralf Boehringer Ingelheim Pharma K.-G., Germany

PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 373 pp.

CODEN: PIXXD2 DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.				KIND DATE				A	PPLI	CATI	DATE						
	WO	2002068420			A1 20020906				WO 2002-EP1820 20020221									
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,
			PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,
			US,	UZ,	VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM	
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,
			CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,
			BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG
	DE 10109021		A	1	20020905			DE 2001-10109021						20010224				
	DΕ	1011	7803		A	1	2002	1024		D:	E 20	01-1	0117	803	2001	0410		•
	DΕ	1014	0345		A	1	2003	0227		D:	E 20	01-1	0140	345	2001	0817		
PRIOR	(TI	APP	LN.	INFO	.:				. :	DE 2	001-	1010	9021	Α	2001	0224		
							•			DE 2	001-	1011	7803	Α	2001	0410		
									:	DE 2	001-	1014	0345	Α	2001	0817		
										DE 2	002-	1020	3486	Α	2002	0130		

OTHER SOURCE(S): MARPAT 137:216824

GI

$$R^{1}$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{4}
 R^{2}
 R^{4}
 R^{4}
 R^{2}
 R^{4}
 R^{4

Xanthine derivs. of formula I [R1, R2 = H, alkyl, alkenyl, etc.; R3 = AB alkyl, arylalkyl, etc.; R4 = heterocyclyl, cycloalkyl, aminoalkyl, etc.] are prepd. which exhibit an inhibitory effect on the activity of the dipeptidylpeptidase-IV enzyme. Pharmaceutical compns. contg. I are described. Thus, II was prepd. and had an IC50 of 22 nM against dipeptidylpeptidase-IV.

IT 454706-71-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of xanthine derivs. as dipeptidylpeptidase-IV inhibitors)

RN 454706-71-9 HCAPLUS

CN 1H-Purine-2,6-dione, 7-(2,3-dimethyl-2-butenyl)-3,7-dihydro-1,3-dimethyl-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

2

ACCESSION NUMBER: 1987:95577 HCAPLUS

DOCUMENT NUMBER: 106:95577

TITLE: Synthesis and biological activity of 3-methyl, 7- or

8-alkyl-, 7,8-dialkyl, heterocyclic, and

cyclohexylaminoxanthines

AUTHOR(S): Romanenko, N. I.; Fedulova, I. V.; Primenko, B. O.;

Orestenko, L. P.

CORPORATE SOURCE: Zaporozh. Med. Inst., Zaporozhe, USSR

SOURCE: Farmatsevtichnii Zhurnal (Kiev) (1986), (5), 41-4

CODEN: FRZKAP; ISSN: 0367-3057

DOCUMENT TYPE: Journal LANGUAGE: Ukrainian

OTHER SOURCE(S): CASREACT 106:95577

Ι

GI

$$\begin{array}{c|c}
O & R^1 \\
N & N
\end{array}$$

$$\begin{array}{c|c}
R^2 \\
N & N
\end{array}$$
Me

AB Seventeen title compds. (I; R1 = heptyl, nonyl, or CH2CH:C(Cl)Me; R2 = NMe2, NEt2, piperidino, cyclohexylamino, NHCH2Ph, piperazino, morpholino, NHNH2, N(CH2CH2OH)2, etc.) were prepd. by reacting the K salt of 8-bromo-3-methylxanthine with appropriate alkyl halides followed by condensation with appropriate primary or secondary amines. Toxicity studies in mice showed I to be less toxic than aminazine. Most I exhibited diuretic activity in rats, and some exhibited analeptic activity as well. Many I exhibited antimicrobial activity in vitro against both bacteria and fungi. The most active diuretics contained morpholino,

piperidino, or N-benzyl groups at the 8-position.

IT 106939-21-3P

CN

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(prepn. and pharmacol. of, structure in relation to)

RN 106939-21-3 HCAPLUS

1H-Purine-2,6-dione, 7-heptyl-3,7-dihydro-3-methyl-8-(1-piperazinyl)-

(CA INDEX NAME)